EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Clinical trials for EGFR POSITIVE NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new EGFR POSITIVE NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for EGFR POSITIVE NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can radiation and osimertinib safely control lung cancer spread?
Disease control OngoingThis study looks at whether it is safe to continue the targeted therapy osimertinib while also giving radiation to people with advanced EGFR-positive non-small cell lung cancer. The goal is to manage cancer that has started to grow in a few new spots. Researchers will track side …
Matched conditions: EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for drug-resistant lung cancer: combo therapy enters human testing
Disease control OngoingThis study tests a new drug (APG-1252) combined with a standard targeted therapy (osimertinib) in people with a type of lung cancer that no longer responds to current treatments. About 80 adults with EGFR-positive non-small cell lung cancer will take part. The goal is to find the…
Matched conditions: EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated May 11, 2026 20:40 UTC